CRP and Alzheimer disease: This highly interactive, “personalized medicine” approach – involving a comprehensive evaluation that scores multiple AD deficiencies including miRNA-, mRNA-, and protein-based gene expression alterations, AD-relevant DNA mutations, pro-inflammatory biomarkers (such as C-reactive protein or CRP), and Aβ40- and Aβ42-peptide load in the CSF and blood serum, combined with data from MRI- and PET-based brain imaging, and familial, clinical history, lifestyle, and other factors could be extremely useful in the improved diagnosis of AD susceptibility and development (52–58).